Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segments: Companion Animal, Production Animal U.S., Production Animal Rest of World, and Contract Manufacturing. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for breeding programs in dairy and beef cows; and Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product aids in the treatment of OA for dogs, as well as Reviderm, an anti-microbial liquid bandage for use in companion animals. The company is also developing various products, such as PAR121 for bone-related diseases and injuries in dogs, cats, and horses; and PAR122 for atopic dermatitis and other dermatological conditions, as well as PROCEPT, a next generation breeding program. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61-2-9667-4411
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.67 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Parnell Pharmaceuticals (OTCMKTS:PARNF) Frequently Asked Questions
What is Parnell Pharmaceuticals' stock symbol?
Parnell Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARNF."
Has Parnell Pharmaceuticals been receiving favorable news coverage?
News headlines about PARNF stock have trended positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Parnell Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Parnell Pharmaceuticals.
Who are some of Parnell Pharmaceuticals' key competitors?
Some companies that are related to Parnell Pharmaceuticals include Cellectar Biosciences (CLRB), Lipocine (LPCN), GT Biopharma (GTBP), Acura Pharmaceuticals (ACUR), Earth Science Tech (ETST), Kaya (KAYS), Neurotrope (NTRP), iCo Therapeutics (ICOTF), Novus Therapeutics (NVUS), NeuroVive Pharmaceutical (NEVPF), BENITEC BIOPHAR/S (BNTC), Sonoma Pharmaceuticals (SNOA), Trillium Therapeutics (TRIL), Capricor Therapeutics (CAPR) and Integrated BioPharma (INBP).
What other stocks do shareholders of Parnell Pharmaceuticals own?
Who are Parnell Pharmaceuticals' key executives?
Parnell Pharmaceuticals' management team includes the folowing people:
- Dr. Alan Richard Bell, Exec. Chairman (Age 63)
- Mr. Brad R. McCarthy, CEO, CFO, Chief Accounting Officer & Exec. Director (Age 43)
How do I buy shares of Parnell Pharmaceuticals?
Shares of PARNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Parnell Pharmaceuticals' stock price today?
One share of PARNF stock can currently be purchased for approximately $0.15.
How big of a company is Parnell Pharmaceuticals?
What is Parnell Pharmaceuticals' official website?
How can I contact Parnell Pharmaceuticals?
Parnell Pharmaceuticals' mailing address is UNIT 4 CENTURY ESTATE 476 GARDENERS ROAD, ALEXANDRIA C3, 2015. The company can be reached via phone at 61-2-9667-4411 or via email at [email protected]
MarketBeat Community Rating for Parnell Pharmaceuticals (OTCMKTS PARNF)
MarketBeat's community ratings are surveys of what our community members think about Parnell Pharmaceuticals and other stocks. Vote "Outperform" if you believe PARNF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PARNF will underperform the S&P 500 over the long term. You may vote once every thirty days.
